Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Viruses On The Verge Of Joining The War On Cancer

This article was originally published in Start Up

Executive Summary

With new approaches in development that add or subtract genetic material to viruses, or arm them with immune-boosting proteins, oncolytic viruses may become the next modality for treating cancer. Several smaller companies and their backers – as well as those who have yet to invest in the space – eagerly await results from Amgen’s Phase III program OncoVex.

You may also be interested in...



UniQure’s Glybera Is First Gene Therapy Okayed In Western Europe

UniQure’s Glybera (alipogene tiparvovec) has become the first gene therapy to be approved for commercialization in the 27-nation European Union, marking a major step towards making such medicines available for treating rare diseases that have a high unmet medical need.

Oncologists Audition Yervoy And Zelboraf For First-line Roles, With New Combos In Near Sight

Cooperative group plans trial testing Yervoy vs. Zelboraf in first-line metastatic melanoma to help settle the issue of which therapy should come first in BRAF-mutation positive patients. New therapies on the way promise to further complicate decision-making.

Natural Products: Back In Vogue?

Several small biotechs are heading back to nature, spotting promising drug targets in exotic plants, sea creatures, and venomous animals, even as Big Pharma and venture capital remain skeptical of the approach.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC092261

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel